Newsroom

Madhushree Ghosh

Precision medicine reduces unnecessary risks to patients including hazardous side effects as well as ineffective treatments (“trial and error” medicine).

We often hear “Don’t take anything personally”. However, that is not the case in terms of precision medicine. In 2015, the U.S. government launched the "Precision Medicine Initiative".

As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.

In the oncology biomarker field, there are obvious trends in technology and markers as well as testing strategies.

We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.

The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.

Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.